22 recruiting, 5 active not recruiting, 4 not yet recruiting, 2 completed. 35 Phase 2, 11 Phase 1.
Follow Large B-cell Lymphoma: new trials by email Literature Review of Large B-cell Lymphoma trials Research Report on Large B-cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2 Trial of CD70.CAR NK Cells for Patients With Primary Refractory or Early Relapsed Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma Fludarabine, Cyclophosphamide, CD70.CAR NK Cells - Large B-cell Lymphoma, Hodgkin Lymphoma | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 100 | 2026-12-28 | 2026-07-15 |
| GLORY: Glofit-GemOx With Liso-Cel For Lymphoma Obinutuzumab, Glofitamab, Gemcitabine & oxaliplatin - Lymphoma, B-cell Lymphomas | Phase 2 | Recruiting | Massachusetts General Hospital | 56 | 2026-09-15 | 2026-10-22 |
| Pola-R-CHP Plus Sonrotoclax in Untreated BCL2-High/Double-Hit LBCL Polatuzumab Vedotin, Rituximab, Cyclophosphamide - Large B-cell Lymphoma | Phase 1 / Phase 2 | Not yet recruiting | Ruijin Hospital | 40 | 2026-06-15 | 2026-06-30 |
| LME-Guided Precision Combination Therapy in B-cell Lymphoma Patients After CD19 CAR-T Failure LME-Guided Combination Therapy Regimen, Glofitamab Monotherapy - Large B-cell Lymphoma | Phase 2 | Not yet recruiting | Ruijin Hospital | 60 | 2026-05-14 | 2026-05-22 |
| Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell Lymphoma Leukapheresis, Lymphodepleting Chemotherapy - Large B-cell Lymphoma | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 50 | 2026-03-17 | 2026-06-30 |
| Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma Epcoritamab, Loncastuximab Tesirine - Large B-cell Lymphoma, Relapse | Phase 2 | Recruiting | University of Miami | 26 | 2026-01-07 | 2026-10-15 |
| The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical Study Glofitamab, PD-1 Inhibitor, Lenalidomide - Large B-cell Lymphoma, TP53 | Phase 2 | Recruiting | The First Affiliated Hospital with Nanjing Medical University | 24 | 2025-09-01 | 2025-11-20 |
| A Study to Evaluate Zanubrutinib and Tislelizumab in Progressive Lymphoma Post CAR-T Tislelizumab, Zanubrutinib, Tislelizumab + Zanubrutinib - Large B-cell Lymphoma | Phase 2 | Recruiting | University Health Network, Toronto | 76 | 2025-06-04 | 2026-06-09 |
| Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) Dose Level 1, VNX-101, Dose Level 2, VNX-101, Dose Level 3, VNX-101 - B-cell Acute Lymphoblastic Leukemia, Large B-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Vironexis Biotherapeutics Inc. | 32 | 2025-05-30 | 2026-10-26 |
| Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym Tafasitamab, Lenalidomide - Large B-cell Lymphoma | Phase 2 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 28 | 2025-03-19 | 2026-04-03 |
| A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies Surovatamig, Prednisone (or equivalent), Rituximab - Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma | Phase 1 / Phase 2 | Recruiting | AstraZeneca | 408 | 2025-01-30 | 2026-10-28 |
| Emapalumab Prevention of CAR-T Cell Associated Toxicities Emapalumab, Cyclophosphamide, Fludarabine Phosphate - Large B-cell Lymphoma, Relapsed Non-Hodgkin Lymphoma | Phase 2 | Recruiting | Marcela V. Maus, M.D.,Ph.D. | 28 | 2024-09-18 | 2026-10-06 |
| CAR T-cell Therapy in Combination With Glofitamab for Relapsed/Refractory Large B-Cell Lymphoma With High-Risk Prognostic Factors CAR T-cell therapy, Glofitamab, Obinutuzumab - Large B-cell Lymphoma | Phase 2 | Not yet recruiting | Ruijin Hospital | 45 | 2024-09-01 | 2024-08-22 |
| A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab As a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma Glofitamab, Polatuzumab vedotin, Obinutuzumab - Large B-cell Lymphoma | Phase 2 | Recruiting | University College, London | 99 | 2024-08-16 | 2024-12-24 |
| CD19-targeted CAR T Cells for Relapsed or Refractory (R/R) Large B-cell Lymphoma Relma-cel - Non-Hodgkin Lymphoma, Large B-cell Lymphoma | Phase 2 | Recruiting | Shanghai Ming Ju Biotechnology Co., Ltd. | 12 | 2024-08-15 | 2024-08-21 |
| A Study of Atlacabtagene Autoleucel CAR T-cells for Adults With Relapsed Large B-cell Lymphoma Fludarabine, Cyclophosphamide, WZTL-002 CAR T-cells - Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 2 | Recruiting | Malaghan Institute of Medical Research | 60 | 2024-07-12 | 2026-08-07 |
| Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL cemacabtagene ansegedleucel, Fludarabine, Cyclophosphamide - Large B-cell Lymphoma | Phase 2 | Recruiting | Allogene Therapeutics | 250 | 2024-06-18 | 2026-10-30 |
| T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) EB103 - B-Cell Non-Hodgkin's Lymphoma (NHL), Lymphoma, Non-Hodgkins | Phase 1 / Phase 2 | Recruiting | Estrella Immunopharma, Inc. | 27 | 2024-06-01 | 2026-10-01 |
| A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL GFH009, Zanubrutinib - Large B-cell Lymphoma | Phase 1 / Phase 2 | Recruiting | Genfleet Therapeutics (Shanghai) Inc. | 51 | 2024-03-20 | 2025-08-12 |
| A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies ALETA-001 - Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse | Phase 1 / Phase 2 | Recruiting | Cancer Research UK | 84 | 2024-02-07 | 2025-07-28 |
Showing 20 of 35. Sign in to see all of them.
Lymphoma, Large B-Cell, Diffuse (10) · Lymphoma, Non-Hodgkin (9) · Lymphoma, B-Cell (7) · Lymphoma (6) · Recurrence (6) · Lymphoma, Follicular (5) · Leukemia, Lymphocytic, Chronic, B-Cell (4) · Lymphoma, Mantle-Cell (4) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (3) · Burkitt Lymphoma (2) · Dendritic Cell Sarcoma, Interdigitating (2) · Lymphoma, B-Cell, Marginal Zone (2) · Disease Attributes (1) · Hodgkin Disease (1) · Immune System Diseases (1)
Hemic and Lymphatic Diseases (22) · Lymphatic Diseases (22) · Neoplasms by Histologic Type (22) · Immunoproliferative Disorders (21) · Lymphoproliferative Disorders (21) · Neoplasms (21) · Immune System Diseases (20) · Lymphoma (14) · Pathologic Processes (11) · Pathological Conditions, Signs and Symptoms (11) · Disease Attributes (9) · Lymphoma, B-Cell (9) · Lymphoma, Non-Hodgkin (9) · Hematologic Diseases (6) · Leukemia, Lymphoid (6)
Cyclophosphamide (10) · fludarabine (6) · glofitamab (5) · obinutuzumab (5) · Rituximab (4) · Prednisone (3) · fludarabine phosphate (3) · Doxorubicin (2) · Immunotherapy, Adoptive (2) · Lenalidomide (2) · Leukapheresis (2) · Vincristine (2) · axicabtagene ciloleucel (2) · loncastuximab tesirine (2) · polatuzumab vedotin (2)
M.D. Anderson Cancer Center (5) · Ruijin Hospital (3) · H. Lee Moffitt Cancer Center and Research Institute (2) · Abramson Cancer Center at Penn Medicine (1) · Allogene Therapeutics (1) · AstraZeneca (1) · CRISPR Therapeutics AG (1) · Cancer Research UK (1) · Estrella Immunopharma, Inc. (1) · Genfleet Therapeutics (Shanghai) Inc. (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · KK Women's and Children's Hospital (1) · Lyell Immunopharma, Inc. (1) · Malaghan Institute of Medical Research (1) · Marcela V. Maus, M.D.,Ph.D. (1)
United States (18) · China (10) · Australia (5) · United Kingdom (3) · Canada (2) · France (2) · Germany (2) · Italy (2) · Japan (2) · South Korea (2) · Spain (2) · Taiwan (2) · Austria (1) · Czechia (1) · Denmark (1)
Paolo Strati, MD (2) · Aloysius Ho, MD (1) · Chen-Lung Lin, MD (1) · Dai Chihara, MD (1) · Dai Chihara, MD, PHD (1) · Dehui Zou, Dr. (1) · Frederick Locke, MD (1) · Huilai Zhang (1) · Jeremy Abramson, MD, MMSc (1) · John Kuruvilla, FRCPC (1) · Juan Alderuccio, MD (1) · Keshu Zhou, MD (1) · Matthew Frigault, MD (1) · Melanie Allen, M.Sc. (1)